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squares (OLS) regression and Tobit regression, with utility score as independent
variable, and ordered logistic regression for each item of EQ-5D. Model perfor-
mance was assessed by comparing predicted and observed mean EQ-5D scores in
the validation set, the unadjusted R-squared and the root mean squared error
(RMSE). RESULTS: The OLS regression had the best predictive performance with
R-squared equal to 0.60 and RMSE equal to 0.25. The linear regression model accu-
rately estimated the mean EQ-5D score in the validation set (predicted score 0.32
versus observed score 0.30). RMSE values of 0.26 and 0.31 were obtained with Tobit
model and ordered logistic model. Items with the greatest contribution to variance
in the OLS model were ‘difficulty of tie the laces of my shoes’ (p0.0018), ‘difficulty
to drink without spilling’ (p0.0156) and ‘difficulty to make precise movements’
(p0.0165). CONCLUSIONS: EQ-5D utility scores can be reasonably predicted from
the H-QoL-I, although item wordings are not directly related. The model based on
OLS regression provides the best fitting. Motor functions items contributed the
model to utility predictions.
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OBJECTIVES: In patients with RMS, assess the impact of relapse(s) leading to hos-
pitalization on Health-Related Quality of Life (HR-QoL), fatigue and Health Care
resource utilisation. METHODS: TEMSO (N1088) was designed to assess efficacy
and safety of teriflunomide, a novel oral disease modifier, in RMS patients. Patients
with no relapse, patients with relapse(s) not leading to hospitalisation and patients
with at least one relapse leading to hospitalisation were analysed. The following
patient reported outcomes (PROs) were assessed; utility (EQ5D), PCS and MCS
(Physical and Mental Health Component Summaries) scores of the SF-36, fatigue
(FIS-total score). Also, Emergency Medical Facility Visits (EMFV; a visit to a medical
facility/hospital for emergency care not resulting in an admission) was tracked.
Changes from Baseline for PROs and annual EMFV rate were analysed for a two-
year period. RESULTS: Change from baseline (CfB) in utility in patients with no
relapse was 0.034, CfB in utility in patients with relapse(s) not leading to hospi-
talisation was -0.019(*p10.01) and CfB in utility in patients with relapse(s) leading
to hospitalisation was -0.057(p10.001; p2:ns). Similar results were seen for PCS of
1.0, -1.0 (p10.01) and -3.1(p10.001; p20.05) respectively and for MCS were
respectively 1.8, -1.0(p10.01) and -2.7 (p10.001; p2:ns). This same trend was
observed with FIS total score, (CfB was respectively: -3.0, 1.4 (p1:ns) and 10.3
(p10.001; p20.01). The mean annual EMFV rate in patients with no relapse was
0.5 and in patients with relapse not leading to hospitalisation was 0.4 (p1:ns). This
rate was increased to 1.2 (p10.05; p20.001) in patients with relapse leading to
hospitalisation. CONCLUSIONS: In TEMSO, patients with relapse leading to hospi-
talisation comparatively have worsening in HR-QoL (EQ-5D, SF-36), fatigue and
have a higher number of EMFV. *p1: versus patients with no relapse, p2: versus
patients with relapse not leading to hospitalisation.
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OBJECTIVES: The original SAT is a five-item questionnaire developed to assess
treatment benefits associated with application of QUTENZA™, a novel high-dose
capsaicin patch, in clinical trials among patients with neuropathic pain . The ob-
jective of this study was to evaluate the item performance and psychometric prop-
erties of the SAT. METHODS: The SAT, Numerical Pain Rating Scale (NPRS), SF-36,
Brief Pain Inventory and Patient Global Impression of Change (PGCI) scores were
measured in two 12 week Phase3 clinical trials. Descriptive statistics, exploratory
and confirmatory factor analysis (EFA and CFE) were conducted to assess the item
performance and to explore the underlying constructs. Reliability and validity were
also examined. RESULTS: Pooled data from 698 patients (21-91 years) completing
SAT after 12 weeks of treatment were analyzed. From descriptive statistics, EFA
and CFA results, a one-factor model combining 4 of the 5 items emerged as the
optimal solution with 66% explained variance. The internal consistency reliability
was high (Cronbach’s alpha  0.87). Construct validity was demonstrated by mod-
erate to high correlations with change in the NPRS (-0.55 pain now and -0.64 aver-
age pain), BPI (-0.59 worst pain, -0.35 activity limitation), SF 36v2 pain subscale
(0.43) and PGIC (0.85). SAT scores strongly discriminated patient change groups
using the PGIC; mean SAT scores were 1.7 in patients who were very much im-
proved versus -1.0 in patients who were much worse/very much worse.
CONCLUSIONS: Preliminary analyses indicate that the measurement properties of
the four-item version of SAT are valid and reliable for patients self assessment of
treatment with QUTENZA™ among patients with neuropathic pain. The item per-
formance suggests that the questionnaire could be further improved with addi-
tional patient input to clarify some of the questions as well as revising the response
options and recall period to better reflect treatment benefits during the course of a
trial.
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OBJECTIVES: The original 40-question Fabry-specific Paediatric Health and Pain
Questionnaire (FPHPQ) was developed to understand and assess the symptoms in
Fabry Disease (FD) patients as no validated instrument existed. The objective of
this study was to evaluate the psychometric properties of the FPHPQ. METHODS:
FPHPQ data were collected from the FOS, a registry sponsored by Shire HGT for
patients with FD who were treatment naive or receiving enzyme replacement ther-
apy with agalsidase alfa. Descriptive statistics and exploratory factor analysis were
conducted to assess the item performance and to explore the underlying con-
structs. Reliability, validity, and responsiveness were also examined. RESULTS:
Eighty-seven children (aged 4-18 years) from 8 different countries completed the
questionnaire. From descriptive statistics and EFA, 23 items in three subscales
emerged: Pain associated with heat or exertion; pain associated with cold; abdom-
inal pain and fatigue. Internal consistency reliability for all three subscales was
good (Cronbach alpha  0.84) and high for all age groups (4-7, 8-12, 13-18 years).
Test-retest reliability was high for all three subscales (intraclass correlation coef-
ficient  0.74). Construct validity was demonstrated by moderate correlation with
the Brief Pain Inventory (BPI), KINDL, and EQ-5D. Known group validity showed that
all subscales were able to discriminate between mild and moderate FD severity as
classified by the FOS MSSI (Mainz Severity Score Index). The FPHPQ heat and exer-
tion subscale was responsive to change in symptoms between responders and
non-responders as defined by change in EQ-5D index scores between Visits 1 and 2.
CONCLUSIONS: Preliminary analyses indicate that the measurement properties of
FPHPQ are valid and reliable for assessing patient-reported symptoms of FD. The
questionnaire could be a useful tool for clinicians to understand the progression of
disease and monitor treatment effects. FPHPQ will be further validated and refined
as the FOS database is continuously adding more patients.
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OBJECTIVES: PatientsLikeMe is an online health-data sharing community and re-
search platform for patients with chronic and life-changing health conditions. In
developing the PatientsLikeMe online platform for patients with Multiple Sclerosis
(MS), we required a patient-reported, multi-dimensional assessment of functional
status that was easy to complete. Existing measures of functional status were
inadequate; clinician-reported, focused on walking, and burdensome to complete.
To develop a longitudinal record accessible to patients using the site, we developed
the Multiple Sclerosis Rating Scale (MSRS). METHODS: We adapted a clinician-
rated measure, the Guy’s Neurological Disability Scale, to a self-report scale and
deployed it to an online community. As part of our validation process, we reviewed
online forum discussions between patients, conducted in-person patient cognitive
debriefing, and made minor improvements to form a revised scale (MSRS-R). The
MSRS-R was deployed as a cross-sectional survey to 4382 patients with relapsing-
remitting MS (RRMS) on the PatientsLikeMe platform. The survey included the
MSRS-R as well as a range of comparator MS measures: PRIMUS, MSIS-29, PDDS,
NARCOMS Performance Scales, and MSWS-12. RESULTS: In total, 816 RRMS pa-
tients responded. The MSRS-R exhibited high internal consistency (Cronbach’s
alpha 0.86) and 1-week retest reliability (r 0.91). The MSRS-R walking item was
highly correlated with alternative walking measures (PDDS, r 0.84; MSWS-12, r
0.83; NARCOMS mobility question, r 0.86). The MSRS-R correlated well with com-
parison instruments, and reliably differentiated between participants by PDDS dis-
ease stage, relapse severity, and time since diagnosis. Retrospective scoring of
most recent relapse suggested a 3-point increase in MSRS-R might usefully identify
relapses. CONCLUSIONS: The MSRS-R is a concise, multi-faceted measure of MS-
related functional disability. It may be useful for describing the impact of MS and
can support further inquiry into the factors that relate to variation in outcomes
among MS patients.
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OBJECTIVES: The Huntington Quality of Life Instrument (H-QoL-I) is a first self-
reported specific Health-Related Quality of Life (HR-QoL) instrument developed to
assess the QoL of patients suffering from Huntington’s disease. It was originally
developed and validated in French and in Italian. The instrument is being validated
in 11 languages. This study aims to validate the German, Polish and US versions of
H-QoL-I cross-culturally. METHODS: The original questionnaire was based on 11
items and 3 dimensions. The instrument was translated forwards and backwards
by native speakers. It was then reviewed and adjusted by local clinicians and tested
for face validity. A survey was conducted with 134 US, 60 Polish and 41 German
patients. Face validity was tested through item completion and overall under-
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